Risk Factors for Linezolid Resistance in Staphylococcus Aureus - Full Text View

Sponsor:	University of Pittsburgh
Information provided by:	University of Pittsburgh
ClinicalTrials.gov Identifier:	NCT00519025

Purpose

This is a retrospective chart review study. The proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed.

Condition
Linezolid Resistance Staphylococcus Aureus

Study Type:	Observational
Study Design:	Cohort, Retrospective
Official Title:	Risk Factors for Linezolid Resistance in Staphylococcus Aureus

Resource links provided by NLM:

Drug Information available for: Linezolid

U.S. FDA Resources

Further study details as provided by University of Pittsburgh:

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	360
Study Start Date:	August 2007
Estimated Study Completion Date:	July 2010

Detailed Description:

This is a retrospective chart review study. The proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed. This research is important because identification of risk factors may allow earlier initiation of appropriate therapy in patients infected with these bacteria. Additionally, we will identify whether horizontal spread is responsible for this increasing trend.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

linezolid resistance to staph aureus

Criteria

Inclusion Criteria:

patients with linezolid resistance to staphylococcus aureus

Exclusion Criteria:

those that don't meet entry criteria

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00519025

Contacts

Contact: Brian Potoski, PharmD	412-648-6487	potoskiba@upmc.edu
Contact: Diana Lynn Pakstis, RN, BSN	412-648-6553	pakstisdl@dom.pitt.edu

Locations

United States, Pennsylvania
University of Pittsburgh Medical Center	Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Brian Potoski, PharmD 412-648-6487 potoskiba@upmc.edu
Contact: Diana Lynn Pakstis, RN, BSN 412-648-6553 pakstisdl@dom.pitt.edu
Principal Investigator: Brian Potoski, PharmD

Sponsors and Collaborators

University of Pittsburgh

Investigators

Principal Investigator:

Brian Potoski, PharmD

University of Pittsburgh

More Information

No publications provided

Responsible Party:	UPMC ( Brian Potoski, Pharm D )
Study ID Numbers:	PRO07080006, investigator funding
Study First Received:	August 17, 2007
Last Updated:	April 7, 2009
ClinicalTrials.gov Identifier:	NCT00519025 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Pittsburgh:

Linezolid
Staphylococcus Aureus
Infections

Additional relevant MeSH terms:

Bacterial Infections
Protein Synthesis Inhibitors
Anti-Infective Agents
Staphylococcal Infections
Gram-Positive Bacterial Infections

Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Enzyme Inhibitors
Linezolid
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 22, 2009